StockTipsArenaBeta

BUY Piramal Pharma Limited — Ruchit Jain, Motilal Oswal

BUYPiramal Pharma Limited
Piramal Pharma share price target & all analyst calls

byRuchit Jain, Motilal OswalHorizon: NA (inferred 1–3 months)6 Aug 2026via Business Today

Entry₹208.93Inferred
Target₹235
Total upside +12.48%
Stop lossNot given
CMP₹196.9Just now
Active-5.76%+19.35%upside left 4 wk left
Follow Ruchit Jain for new calls(46% target hit, 24 closed calls)Get alertsWatch PPLPHARMA for new buy/sell callsGet alertsSee 1 other Short-term call on PPLPHARMASee 73 other Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 9 Oct, 3:37 pm IST
21 supporting10 neutral8 opposing
Supports the BUY call (21)

4 advisors have active long-term BUY calls on this stock

Advisor consensus · adjacent horizon·24 Sept · 2w ago

Piramal Pharma earns ‘Leader’ ESG rating from independent assessor

NewsGoogle News·18 Sept · 3w ago

(opens in new tab)

1 other SEBI-registered advisor has an active short-term BUY call on this stock

Advisor consensus · same horizon·26 Aug · 1mo ago

Neutral / worth noting (10)

These four pharma stocks will be reacting to important news updates today

NewsCnbc-Tv18·5 Oct · 4d ago

(opens in new tab)

Piramal Pharma gets 7 observations from US FDA at Morpeth UK facility

NewsCnbc-Tv18·14 Sept · 3w ago

(opens in new tab)
Weighs against the BUY call (8)

MACD below its signal line — bearish momentum

Technicals · macd·9 Oct · today

Piramal Pharma received a GST order demanding Rs 4.06 crore in input tax credit plus an equivalent penalty of Rs 4.06 crore. The company plans to appeal the order and does not expect a material impact

NSE · Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company·29 Sept · 1w ago

(opens in new tab)

Piramal Pharma shares fall 3% after USFDA issues 7 observations at UK facility

NewsCnbc-Tv18·15 Sept · 3w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Piramal Pharma

All analyst calls on Piramal Pharma

More from Ruchit Jain, Motilal Oswal

Every call and its outcome